Loading...
XNAS
APDN
Market cap2mUSD
Jul 09, Last price  
5.12USD
1D
-3.40%
1Q
365.45%
Jan 2017
-99.65%
IPO
-100.00%
Name

Applied DNA Sciences Inc

Chart & Performance

D1W1MN
P/E
P/S
0.77
EPS
Div Yield, %
Shrs. gr., 5y
143.75%
Rev. gr., 5y
-8.63%
Revenues
3m
-74.33%
018,900121,920873,010295,162519,844968,8481,854,6942,036,2222,721,2249,008,4994,186,4274,751,2603,903,3435,389,0891,931,4979,027,73818,168,67713,367,4433,431,420
Net income
-7m
L-29.70%
-52,610,380-2,410,237-13,304,833-6,802,8983,944,578-7,909,600-10,515,124-7,150,712-17,686,472-13,066,661-11,881,137-12,175,979-12,855,767-11,692,928-8,632,446-12,764,974-16,029,225-8,377,996-9,947,059-6,992,521
CFO
-14m
L+120.52%
-9,116,045-2,883,815-2,251,580-2,926,280-2,468,598-2,455,189-3,761,716-3,960,679-7,870,353-8,512,738-6,965,846-9,896,727-7,479,184-6,917,209-6,861,772-11,143,059-13,387,955-8,976,706-6,217,677-13,711,397
Earnings
Aug 06, 2025

Profile

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
IPO date
Aug 24, 2001
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
3,431
-74.33%
13,367
-26.43%
18,169
101.25%
Cost of revenue
6,008
11,569
17,041
Unusual Expense (Income)
NOPBT
(2,577)
1,798
1,128
NOPBT Margin
13.45%
6.21%
Operating Taxes
137
108
Tax Rate
9.57%
NOPAT
(2,714)
1,798
1,020
Net income
(6,993)
-29.70%
(9,947)
18.73%
(8,378)
-47.73%
Dividends
(233)
(110)
Dividend yield
Proceeds from repurchase of equity
13,398
952
14,427
BB yield
Debt
Debt current
546
499
Long-term debt
932
1,977
Deferred revenue
194
Other long-term liabilities
545
4,316
5,171
Net debt
(4,953)
(4,676)
(15,215)
Cash flow
Cash from operating activities
(13,711)
(6,218)
(8,977)
CAPEX
(408)
(1,141)
(490)
Cash from investing activities
(408)
(1,096)
(490)
Cash from financing activities
13,399
18,127
FCF
(1,931)
2,488
2,749
Balance
Cash
6,431
7,152
15,215
Long term investments
Excess cash
6,260
6,483
14,307
Stockholders' equity
(309,837)
(302,512)
(292,490)
Invested Capital
320,090
313,133
310,570
ROIC
0.58%
0.34%
ROCE
15.91%
6.24%
EV
Common stock shares outstanding
3,966
654
448
Price
Market cap
EV
EBITDA
(1,880)
3,161
2,418
EV/EBITDA
Interest
13,218
Interest/NOPBT
1,172.20%